Fintel reports that on July 17, 2025, Morgan Stanley upgraded their outlook for Amicus Therapeutics (NasdaqGM:FOLD) from Equal-Weight to Overweight.

Analyst Price Forecast Suggests 163.26% Upside

As of July 16, 2025, the average one-year price target for Amicus Therapeutics is $15.98/share. The forecasts range from a low of $9.09 to a high of $23.10. The average price target represents an increase of 163.26% from its latest reported closing price of $6.07 / share.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for Amicus Therapeutics is 746MM, an increase of 37.33%. The projected annual non-GAAP EPS is 0.39.

What is the Fund Sentiment?

There are 546 funds or institutions reporting positions in Amicus Therapeutics. This is an decrease of 9 owner(s) or 1.62% in the last quarter. Average portfolio weight of all funds dedicated to FOLD is 0.20%, an increase of 6.86%. Total shares owned by institutions increased in the last three months by 0.55% to 364,819K shares. The put/call ratio of FOLD is 0.24, indicating a bullish outlook.

What are Other Shareholders Doing?

Wellington Management Group Llp holds 29,201K shares representing 9.48% ownership of the company. In its prior filing, the firm reported owning 28,462K shares , representing an increase of 2.53%. The firm decreased its portfolio allocation in FOLD by 6.65% over the last quarter.

Perceptive Advisors holds 21,465K shares representing 6.97% ownership of the company. In its prior filing, the firm reported owning 24,246K shares , representing a decrease of 12.96%. The firm decreased its portfolio allocation in FOLD by 1.96% over the last quarter.

VGHCX - Vanguard Health Care Fund Investor Shares holds 20,894K shares representing 6.79% ownership of the company. No change in the last quarter.

Avoro Capital Advisors holds 20,500K shares representing 6.66% ownership of the company. In its prior filing, the firm reported owning 23,175K shares , representing a decrease of 13.05%. The firm decreased its portfolio allocation in FOLD by 15.44% over the last quarter.

William Blair Investment Management holds 14,779K shares representing 4.80% ownership of the company. In its prior filing, the firm reported owning 15,598K shares , representing a decrease of 5.54%. The firm decreased its portfolio allocation in FOLD by 5.67% over the last quarter.

Amicus Therapeutics Background Information
(This description is provided by the company.)

Amicus Therapeutics is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases.